185 related articles for article (PubMed ID: 30197173)
1. Preliminary activity of capmatinib with gefitinib in NSCLC.
Burki TK
Lancet Oncol; 2018 Oct; 19(10):e517. PubMed ID: 30197173
[No Abstract] [Full Text] [Related]
2. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.
Zhang YQ; Jiang LJ; Jiang SX; Xu YF; Zhou BB; Huang GH; Liu DM; Wang Y; Fan WZ; Li JP; Wang B
J Vasc Interv Radiol; 2019 Jul; 30(7):1004-1012. PubMed ID: 31171399
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Hirsch FR; Sequist LV; Gore I; Mooradian M; Simon G; Croft EF; DeVincenzo D; Munley J; Stein D; Freivogel K; Sifakis F; Bunn PA
Cancer; 2018 Jun; 124(11):2407-2414. PubMed ID: 29579334
[TBL] [Abstract][Full Text] [Related]
5. CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e516. PubMed ID: 30197172
[No Abstract] [Full Text] [Related]
6. Molecular selection trumps clinical selection.
Shepherd FA
J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
[No Abstract] [Full Text] [Related]
7. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
[TBL] [Abstract][Full Text] [Related]
8. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
9. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
13. Alectinib shows CNS efficacy in ALK-positive NSCLC.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e520. PubMed ID: 30245054
[No Abstract] [Full Text] [Related]
14. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Lokiec F; Douillard JY
Rev Pneumol Clin; 2011 Jun; 67 Suppl 1():S15-9. PubMed ID: 21777761
[TBL] [Abstract][Full Text] [Related]
16. EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?
Mormile R
Pathol Oncol Res; 2019 Oct; 25(4):1665-1666. PubMed ID: 30661223
[No Abstract] [Full Text] [Related]
17. Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.
Tan EH; Lim WT; Ahn MJ; Ng QS; Ahn JS; Shao-Weng Tan D; Sun JM; Han M; Payumo FC; McKee K; Yin W; Credi M; Agarwal S; Jac J; Park K
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):532-542. PubMed ID: 29346833
[TBL] [Abstract][Full Text] [Related]
18. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.
Gainor JF; Stevens SE; Willers H; Shih HA; Heist RS
J Thorac Oncol; 2020 Jan; 15(1):e8-e10. PubMed ID: 31864558
[No Abstract] [Full Text] [Related]
19. Clairvoyance or reliable prediction of the future?
van Zandwijk N; van de Vijver MJ
Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
[No Abstract] [Full Text] [Related]
20. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]